Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05332366 · ClinicalTrials.gov registry record · Phase 2
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT05332366 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 35 participants.
The verdict
NCT05332366, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This purpose of this trial was to investigate the molecular signature of frontal fibrosing alopecia (FFA) and the effect of delgocitinib cream 2% on reversing the FFA disease signature in active lesions. The trial also investigated the clinical effect of delgocitinib cream on FFA compared to a placebo cream.
Interventions
- DRUG Delgocitinib cream
- DRUG Delgocitinib cream vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2023-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05332366
The ClinicalTrials.gov registry entry for NCT05332366 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Delgocitinib cream is the first listed.
NCT05332366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05332366 about?
NCT05332366 is a clinical study titled "A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia". This purpose of this trial was to investigate the molecular signature of frontal fibrosing alopecia (FFA) and the effect of delgocitinib cream 2% on reversing the FFA disease signature in active lesions. The trial also investigated the clinical effect of delgocitinib cream on FFA compared to a place...
What is the current status of trial NCT05332366?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2022-04-19. Estimated completion is 2023-05-22.
What interventions are being tested in trial NCT05332366?
The interventions under investigation include: Delgocitinib cream (DRUG), Delgocitinib cream vehicle (DRUG).
Who is sponsoring clinical trial NCT05332366?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.